Vectors Research Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $210K | Buy |
8,726
+74
| +0.9% | +$1.94K | 0.05% | 143 |
|
|
2026
Q1 | $243K | Buy |
+8,652
| New | +$230K | 0.07% | 128 |
|
|
2025
Q4 | – | Sell |
-7,965
| Closed | -$203K | – | 131 |
|
|
2025
Q3 | $203K | Buy |
+7,965
| New | +$197K | 0.06% | 130 |
|
|
2025
Q2 | – | Sell |
-9,028
| Closed | -$229K | – | 122 |
|
|
2025
Q1 | $229K | Hold |
9,028
| – | – | 0.08% | 105 |
|
|
2024
Q4 | $240K | Sell |
9,028
-3,150
| -26% | -$85.4K | 0.08% | 110 |
|
|
2024
Q3 | $351K | Hold |
12,178
| – | – | 0.11% | 102 |
|
|
2024
Q2 | $341K | Sell |
12,178
-57
| -0.5% | -$1.57K | 0.1% | 106 |
|
|
2024
Q1 | $340K | Buy |
12,235
+200
| +2% | +$5.55K | 0.1% | 114 |
|
|
2023
Q4 | $349K | Sell |
12,035
-300
| -2% | -$9.07K | 0.1% | 116 |
|
|
2023
Q3 | $391K | Sell |
12,335
-2,067
| -14% | -$73.1K | 0.13% | 103 |
|
|
2023
Q2 | $528K | Sell |
14,402
-2,115
| -13% | -$82.3K | 0.15% | 104 |
|
|
2023
Q1 | $674K | Sell |
16,517
-618
| -4% | -$26.7K | 0.17% | 92 |
|
|
2022
Q4 | $878K | Sell |
17,135
-33
| -0.2% | -$1.58K | 0.23% | 82 |
|
|
2022
Q3 | $751K | Sell |
17,168
-576
| -3% | -$28K | 0.21% | 81 |
|
|
2022
Q2 | $930K | Sell |
17,744
-94
| -0.5% | -$4.79K | 0.24% | 84 |
|
|
2022
Q1 | $923K | Sell |
17,838
-892
| -5% | -$46.3K | 0.2% | 89 |
|
|
2021
Q4 | $1.11M | Buy |
18,730
+2,457
| +15% | +$122K | 0.23% | 89 |
|
|
2021
Q3 | $700K | Sell |
16,273
-1,150
| -7% | -$50.9K | 0.16% | 100 |
|
|
2021
Q2 | $682K | Buy |
17,423
+140
| +0.8% | +$5.44K | 0.17% | 101 |
|
|
2021
Q1 | $626K | Buy |
17,283
+2,621
| +18% | +$93.1K | 0.17% | 102 |
|
|
2020
Q4 | $540K | Sell |
14,662
-2,612
| -15% | -$95.8K | 0.17% | 91 |
|
|
2020
Q3 | $498K | Buy |
17,274
+2,967
| +21% | +$104K | 0.18% | 86 |
|
|
2020
Q2 | $444K | Buy |
14,307
+1,202
| +9% | +$40.8K | 0.18% | 87 |
|
|
2020
Q1 | $406K | Sell |
13,105
-3,284
| -20% | -$112K | 0.19% | 82 |
|
|
2019
Q4 | $609K | Sell |
16,389
-5,349
| -25% | -$191K | 0.25% | 71 |
|
|
2019
Q3 | $741K | Sell |
21,738
-1,021
| -4% | -$37.1K | 0.36% | 54 |
|
|
2019
Q2 | $935K | Buy |
22,759
+2
| +0% | +$79 | 0.51% | 44 |
|
|
2019
Q1 | $917K | Buy |
22,757
+6,272
| +38% | +$251K | 0.52% | 44 |
|
|
2018
Q4 | $683K | Buy |
16,485
+14,188
| +618% | +$589K | 0.33% | 68 |
|
|
2018
Q3 | $792K | Buy |
+2,297
| New | +$88.4K | 0.49% | 47 |
|
Other funds holding PFE
Vectors Research Management's PFE Position: Q2 2026 in Review
Vectors Research Management increased its Pfizer (PFE) stake by 0.86% in Q2 2026, buying an estimated $1.94K and bringing the position to 8,726 shares worth $210K. The position accounts for 0.05% of the portfolio, ranked #143.
Vectors Research Management first reported a position in PFE in Q3 2018 and has held it in 30 quarters since. The position peaked at $1.11M in Q4 2021. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Vectors Research Management held 8,726 shares of Pfizer worth $210K as of Q2 2026.
- Vectors Research Management bought 74 Pfizer shares in Q2 2026, an estimated $1.94K.
- Pfizer made up 0.05% of Vectors Research Management's portfolio in Q2 2026, its #143 holding.
- Vectors Research Management first reported a position in Pfizer in Q3 2018 and has held it in 30 quarters since.
- Vectors Research Management's Pfizer position peaked at $1.11M in Q4 2021.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Vectors Research Management's 13F filing for Q2 2026, filed 29 Jul 2026.